Allogene Therapeutics (ALLO) Assets Average (2019 - 2025)
Historic Assets Average for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $455.2 million.
- Allogene Therapeutics' Assets Average fell 2634.61% to $455.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $455.2 million, marking a year-over-year decrease of 2634.61%. This contributed to the annual value of $595.8 million for FY2024, which is 1863.33% down from last year.
- According to the latest figures from Q3 2025, Allogene Therapeutics' Assets Average is $455.2 million, which was down 2634.61% from $489.3 million recorded in Q2 2025.
- Allogene Therapeutics' Assets Average's 5-year high stood at $1.2 billion during Q1 2021, with a 5-year trough of $455.2 million in Q3 2025.
- In the last 5 years, Allogene Therapeutics' Assets Average had a median value of $761.6 million in 2023 and averaged $797.3 million.
- Per our database at Business Quant, Allogene Therapeutics' Assets Average surged by 7114.63% in 2021 and then crashed by 2634.61% in 2025.
- Over the past 5 years, Allogene Therapeutics' Assets Average (Quarter) stood at $1.1 billion in 2021, then decreased by 19.44% to $858.0 million in 2022, then dropped by 20.97% to $678.1 million in 2023, then dropped by 16.1% to $568.9 million in 2024, then dropped by 19.99% to $455.2 million in 2025.
- Its last three reported values are $455.2 million in Q3 2025, $489.3 million for Q2 2025, and $528.3 million during Q1 2025.